English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduASCO: Treatment options for multiple myeloma are shifting rapidly, with new patients increasingly being treated with a 4-part drug combination that includes a new immunotherapy agent. What does this mean for patients, and how will treatment change in the future?
Tag: ASCO Annual Meeting
ASCO23: Sylvester Cancer Experts Available for Interviews on a Wide Range of Topics
In addition to presenting Sylvester Comprehensive Cancer Center research findings, Sylvester experts are available at ASCO to share perspectives on a wide variety of topics and studies ranging from breast cancer to sarcoma, prostate cancer, mesothelioma, melanoma, CNS tumors and more.
Ibrutinib with chemoimmunotherapy improved progression-free survival for newly diagnosed mantle cell lymphoma patients
Combination chemoimmunotherapy with the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib demonstrated improved progression-free survival over standard chemoimmunotherapy for previously untreated mantle cell lymphoma (MCL) in patients 65 and over, researchers from The University of Texas MD Anderson Cancer Center reported today at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. The study results also were published today in the New England Journal of Medicine.
Cleveland Clinic experts available to comment on cancer research presented at ASCO Annual Meeting
Cleveland Clinic cancer researchers are involved with more than 50 studies that’ll be presented at the virtual American Society of Clinical Oncology (ASCO) Annual Meeting, June 4—8, 2021. Key research from Cleveland Clinic focuses on advancements in the prevention and…
Metabolic inhibitor IACS-6274 shows early antitumor effects in underserved patients with advanced cancers
A metabolic inhibitor drug, IACS-6274, developed by MD Anderson’s Therapeutics Discovery division, is well-tolerated and showed early signs of anti-tumor activity in a Phase I trial being presented at the 2021 ASCO Annual Meeting.
Atlantic Health System Leads Phase 1 Study on CPI-613® (Devimistat), First-in-Class Treatment for Pancreatic Cancer to be Presented at American Society of Clinical Oncology (ASCO) 2020
Dr. Alistar has pioneered the use of CPI-613® (devimistat), a unique first-in-class treatment for locally advanced or metastatic pancreatic cancer, in combination with two chemotherapy drugs. Devimistat uniquely targets enzymes involved in cancer cell metabolism, against pancreatic cancer. The study’s efficacy data suggest devimistat has synergy with chemotherapy.The current study was funded by the drug’s manufacturer, New Jersey-based Rafael Pharmaceuticals and by Atlantic Health System.